

Table S3 Adverse events reported by ≥ 1 participant in Trial B

Preferred Term, n	150 mg (n = 22)	Placebo (n=10)
Participants with ≥ 1 AE	16	5
Contusion	5	1
Dizziness	5	0
Scratch	1	2
Excoriation	2	1
Fatigue	2	0
Nausea	2	0
Diarrhea	2	0
Somnolence	2	0
Increased appetite	2	0
Eye pain	2	0
Vessel puncture site hematoma	1	1
Rhinorrhea	1	0
Erythema	1	0
Lip blister	1	0
Flank pain	1	0
Sunburn	1	0
Nephrolithiasis	1	0
Depressed level of consciousness	1	0
Muscle spasm	1	0

Neck pain	1	0
Abnormal sensation in eye	1	0
Musculoskeletal stiffness	1	0
Rash	1	0
Skin irritation	1	0
Decreased appetite	1	0
Infrequent bowel movements	1	0
Flatulence	1	0
Nodule	1	0
Pruritus	1	0
Pain in extremity	1	0
Muscle tightness	1	0
Myalgia	0	1
Muscle spasms	0	1
Ocular hyperemia	0	1
Sneezing	0	1
Local Swelling	0	1
Edema peripheral	0	1
Periorbital hematoma	0	1
Nasal congestion	0	1